Encompass Health Research and Development Expenses 2012-2026 | EHC

Encompass Health annual/quarterly research and development expenses history and growth rate from 2012 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Encompass Health research and development expenses for the quarter ending March 31, 2026 were $0M, a 0% increase year-over-year.
  • Encompass Health research and development expenses for the twelve months ending March 31, 2026 were $0M, a 0% increase year-over-year.
  • Encompass Health annual research and development expenses for 2025 were $0B, a 0% decline from 2024.
  • Encompass Health annual research and development expenses for 2024 were $0B, a 0% decline from 2023.
  • Encompass Health annual research and development expenses for 2023 were $0B, a 0% decline from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Encompass Health Annual Research and Development Expenses
(Millions of US $)
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Encompass Health Quarterly Research and Development Expenses
(Millions of US $)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $10.662B $5.935B
Encompass Health Corporation is a provider of integrated healthcare services. It offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. The company delivers high-quality, cost-effective, integrated care in the healthcare space. It provides a continuum of facility-based and home-based post-acute services for its patients and their families, which will gain more prevalence as coordinated care and integrated delivery payment models, such as accountable care organizations and bundled payment arrangements. The company operates through two segments: Inpatient Rehabilitation as well as Home Health and Hospice business.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $29.514B 13.37
Quest Diagnostics (DGX) United States $21.197B 19.44
Elanco Animal Health (ELAN) United States $11.500B 24.35
DaVita (DVA) United States $10.023B 13.82
Chemed (CHE) United States $5.639B 19.57
Option Care Health (OPCH) United States $4.553B 18.71
RadNet (RDNT) United States $4.302B 142.13
LifeStance Health (LFST) United States $2.495B 320.00
Addus HomeCare (ADUS) United States $1.719B 16.61
Astrana Health (ASTH) United States $1.536B 31.40
Aveanna Healthcare Holdings (AVAH) United States $1.353B 12.20
U.S Physical Therapy (USPH) United States $1.157B 29.19
Pennant (PNTG) United States $1.072B 31.31
Daxor (DXR) United States $0.048B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.032B 0.00
Psychemedics (PMD) United States $0.000B 0.00